期刊文献+

HPLC-MS/MS法同时测定人血浆中替诺福韦艾拉酚胺及其代谢物替诺福韦的浓度和临床应用 被引量:7

Simultaneous quantitation of tenofovir alafenamide and its metabolite tenofovir in human plasma by HPLC-MS/MS and clinic application
原文传递
导出
摘要 目的:建立快速、灵敏的高效液相色谱-串联质谱(HPLC-MS/MS)方法同时测定人血浆中替诺福韦艾拉酚胺(TAF)及其活性代谢产物替诺福韦(TFV)的浓度,并研究该药物在人体内的药动学特征。方法:采用Capcell pake ADME色谱柱(75 mm×2.1 mm,5μm),以0.1%甲酸水溶液-甲醇为流动相,梯度洗脱,流速0.4mL·min^-1,进样量5μL;采用多反应监测(MRM),选择质荷比(m/z)477.3/346.1(TAF)、288.2/176.0(TFV)、484.3/346.1(内标1:TAF-d7)及294.2/182.0(内标2:TFV-d6)进行检测。结果:TAF与TFV质量浓度分别在0.1~400 ng·mL^-1及0.4~20 ng·mL^-1范围内线性关系良好,定量下限分别为0.100 0ng·mL^-1及0.400 0 ng·mL^-1,日内、日间精密度均小于9.0%,准确度分别为94.1%~99.2%和95.5%~112.8%。健康中国人服用富马酸替诺福韦艾拉酚胺片25 mg后,TAF主要药动学参数:Cmax=(207.97±61.08)ng·mL^-1,T1/2=(0.54±0.15)h,AUC0-∞=(126.07±42.67)h·ng·mL^-1;TFV主要药动学参数:Cmax=(8.76±1.46)ng·mL^-1,T1/2=(29.47±4.16)h,AUC0-∞=(193.19±45.75)h·ng·mL^-1。结论:该方法适用于TAF及其代谢产物TFV的血药浓度检测,并提供药动学参数。 Objective:To develop a selective and rapid HPLC-MS/MS method for simultaneously determination of tenofovir alafenamide(TAF)and its active metabolite,tenofovir(TFV),in human plasma,in order to study the pharmacokinetics in healthy volunteers.Methods:The fractionation of the plasma sample and determination of TAF/TFV was achieved using HPLC-MS/MS equipped with Capcell pake ADME column(75 mm x 2.1 mm,5μm),using 0.1%formic acid water solution and methanol as mobile phase,respectively,by a gradient elution at 0.4 mL·min^-1 flow rate.The mass was captured by multiple reactions monitoring(MRM),with m/z of 477.3/346.1(TAF),288.2/176.0(TFV),484.3/346.1(internal standard 1:TAF-d7)and 294.2/182.0(internal standard 2:TFV-d,)as the characteristic ion masses.Results:Under the concentration range 0.1-400 ng·mL^-1 for TAF and 0.4-20 ng·mL^-1 for TFV,good linearity was achieved with0.100 0ng·mL^-1 and 0.400 0 ng·mL^-1 as lower limit of quantification,respectively.Both inter-and intraday precisions were bellow 9.0%and the accuracy was between 94.1%-99.2%for TAF and 95.5%^(-1)12.8%for TFV.The main pharmacokinetic parameters of TAF and TFV measured in healthy Chinese volunteers after oral administration TAF 25 mg were as follows:C_(max)=(207.97±61.08)ng·mL^-1,(8.76±1.46)ng·mL^-1;T1/2=(0.54±0.15)h,(29.47±4.16)h;AUC_(0-∞)=(126.07±42.67 hng·mL^-1,(193.19±45.75)h·ng·mL^-1.Conclusion:The HPLC-MS/MS method is validated for application in quantification of TAF and its metabolite TFV,and proved adaptable for following pharmacokinetic studies.
作者 胡伟 杨乐婷 蒋学华 王凌 HU Wei;YANG Le-ting;JIANG Xue-hua;WANG Ling(West China School of Pharmacy,Sichuan University,Chengdu 610041,China;Chengdu Finelyse Pharmaceutical Technology Co.,Ltd.,Chengdu 610031,China)
出处 《药物分析杂志》 CAS CSCD 北大核心 2019年第7期1200-1206,共7页 Chinese Journal of Pharmaceutical Analysis
关键词 替诺福韦艾拉酚胺 替诺福韦 核苷类逆转录酶抑制剂 抗病毒药物 活性代谢物 磷酰胺酯前体药物 血浆药物浓度 药动学 高效液相色谱串联质谱法 tenofovir alafenamide tenofovir nucleotide reverse transcriptase inhibitors antiviral agents active metabolite phosphoramide prodrug drug plasma concentration pharmacokinetic HPLC-MS/MS
作者简介 通信作者: 王凌,Tel :( 028 ) 85501370;E-mail: rebeccawang312@gmail.com 第一作者:胡伟, Tel:( 028 ) 85501370;E-mail: sandyhwx@ 163.com
  • 相关文献

参考文献2

二级参考文献10

  • 1Laurent Castera.Hepatitis B: are non‐invasive markers of liver fibrosis reliable?[J].Liver Int.2014
  • 2Sarah A Hughes,Heiner Wedemeyer,Phillip M Harrison.Hepatitis delta virus[J].The Lancet.2011(9785)
  • 3Fabio Tramuto,Carmelo Massimo Maida,Giuseppina M. E. Colomba,Paola Di Carlo,Francesco Vitale,Esteban Martinez.Prevalence of Occult Hepatitis B Virus Infection in a Cohort of HIV-Positive Patients Resident in Sicily, Italy[J].BioMed Research International.2013
  • 4Chloe L. Thio,Laura Smeaton,Melissa Saulynas,Hyon Hwang,Shanmugam Saravan,Smita Kulkarni,James Hakim,Mulinda Nyirenda,Hussain S. Iqbal,Umesh G. Lalloo,Anand S. Mehta,Kimberly Hollabaugh,Thomas B. Campbell,Shahin Lockman,Judith S. Currier.Characterization of HIV–HBV coinfection in a multinational HIV-infected cohort[J].AIDS.2013(2)
  • 5George V. Papatheodoridis.Why do I treat HBeAg‐negative chronic hepatitis B patients with nucleos(t)ide analogues?[J].Liver Int.2013
  • 6.Hepatitis B and long-term HIV outcomes in coinfected HAART recipients[J].AIDS.2009(14)
  • 7Gary M Clifford,Martin Rickenbach,Jerry Polesel,Luigino Dal Maso,Ingrid Steffen,Bruno Ledergerber,Andri Rauch,Nicole M Probst-Hensch,Christine Bouchardy,Fabio Levi,Silvia Franceschi.Influence of HIV-related immunodeficiency on the risk of hepatocellular carcinoma[J].AIDS.2008(16)
  • 8Lionel Piroth,Marie-Edith Lafon,Christine Binquet,Pascale Bertillon,Anne Gervais,Enguerrand Lootvoet,Jean-Marie Lang,Jean Pierre De Jaureguiberry,Geneviève Chene,Catherine Leport,The Anrs Co8 Aproco-Copilote Study Group.Occult hepatitis B in HIV-HCV coinfected patients[J].Scandinavian Journal of Infectious Diseases.2008(10)
  • 9JKRockstroh,SBhagani,YBenhamou,RBruno,SMauss,LPeters,MPuoti,VSoriano,CTural.European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV‐infected adults[J].HIV Medicine.2008(2)
  • 10Christopher J Hoffmann,Chloe L Thio.Clinical implications of HIV and hepatitis B co-infection in Asia and Africa[J].The Lancet Infectious Diseases.2007(6)

共引文献13

同被引文献58

引证文献7

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部